Hengrui advances oncology and ophthalmology pipelines with new approvals
Jiangsu Hengrui Medicine announced significant progress in its oncology and ophthalmology pipelines. Its subsidiary, Suzhou Shengdiya Biomedical, received approval from the National Medical Products Administration (NMPA) to begin clinical trials for SHR-4506 injection, a Class 1 therapeutic biologic intended for the treatment of advanced malignancies. Preclinical studies have demonstrated promising anti-tumor activity. As of now, the cumulative R&D investment in SHR-4506 related projects has reached CNY 19.92 million.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
News Alerts
Get instant email alerts when Jiangsu Hengrui Medicine publishes news
Free account required • Unsubscribe anytime